An earlier stage of trials with the Oxford University and AstraZeneca vaccine suggested that a “similar” immune response was shown among both older and younger adults. Experts have recently revealed however, that the vaccine shows a “strong immune response” among patients who are more elderly.
Data on the immune responses and safety of participants in phase two of the vaccine trial has been submitted for peer review in a medical journal. The findings, however, have been discussed before publication and are very positive, meaning it is considered as one of the forerunners in the Covid-19 vaccine race.
A phase three clinical trial for the vaccine is currently underway, meaning thousands of participants from a number of different countries around the world are testing the safety and effectiveness of the vaccine.
An AstraZeneca spokesperson said, “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher.”
A statement from Oxford University added, “Our ongoing trials will provide further data, but this marks a key milestone and reassures us that the vaccine is safe for use and induces strong immune responses in both parts of the immune system in all adult groups.”
Test Assurance Group (TAG) have developed an end to end testing system that works in a least fuss, user friendly and GDPR compliant manner. TAG have developed a market leading test process and protocol that enables employers to make decisions in real time around their return to work/school process.
For more information about TAG and what we do, please contact us today;
visit www.testassurancegroup.com
call +44 (0)330 124 4371
email enquiries@testassurancegroup.com
follow us on Twitter @TestAssurance and Linked In @Test Assurance Group
Nearly Half of England’s Secondary Schools Report Covid Cases
